July 23: Biosimilars: A 2020 Mid-Year Review

Biologics are the fastest-growing class of therapeutic products in the United States. In 2019, the FDA approved 10 biosimilars—a new record. For pharmaceutical companies, this means that competition in the biosimilars space is heating up and creating a new sense of urgency to innovate.
On July 23, 2020, please join life sciences attorneys John Adkisson, Geoff Biegler, and Jenny Shmuel for a webinar, in which they will provide a mid-year update on the current U.S. biosimilars space. Topics to be discussed include recent developments regarding:

• The U.S. biosimilars market, including approvals and launches
• FDA announcements and guidance
• Select court cases and appellate guidance
• Trends in IPRs.

In addition, our hosts will discuss how the ongoing COVID-19 pandemic has impacted U.S. biosimilars and how it could continue to do so in the future.
Title:
Biosimilars: A 2020 Mid-Year Review
Webinar Date+Time:
Thursday, July 23, 2020
1:30 – 2:30 pm EDT
Register Now!
Speakers:

• John C. Adkisson
• Geoffrey D. Biegler
• Jenny Shmuel, Ph.D.

By:
Fish & Richardson, P.C.
Credit:
Fish & Richardson will apply for 1.0 hour of CLE credit.
Register Now!